FrancophonIA/ELRC3.0 huggingface dataset:
English: The median steady-state Cmax and AUC(0-24) values after administration of 200 mg pazopanib once daily in patients with moderate hepatic impairment were approximately 44% and 39%, of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function, respectively (see Table 7).
Maltese: Il-valuri medjana ta' Cmax u AUC(0-24) fi stat fiss wara għoti ta' 200 mg pazopanib darba kuljum f'pazjenti b'indeboliment epatiku moderat kienu madwar 44% u 39%, rispettivament , tal-valuri medjana korrispondenti wara għoti ta' 800 mg darba kuljum f'pazjenti b'funzjoni epatika normali (ara Tabella 7).
English: In repeat dose studies in rodents, effects in a variety of tissues (bone, teeth, nail beds, reproductive organs, haematological tissues, kidney and pancreas) appear related to the pharmacology of VEGFR inhibition and/or disruption of VEGF signalling pathways, with most effects occurring at plasma exposure levels below those observed in the clinic.
Maltese: Fi studji b'dożi ripetuti fil-firien, effetti f'varjetà ta' tessuti (għadam, snien, l-għerq tad-dwiefer, organi riproduttivi, tessuti ematologiċi, kliewi u frixa) jidhru relatati mal-farmakoloġija tal-inibizzjoni ta' VEGFR u/jew it-taħwid ta' VEGF signalling pathways, bl-aktar effetti jseħħu f'livelli ta' esponiment fil-plażma anqas minn dawk osservati fil-klinika.
English: Results from in vitro studies demonstrated that metabolism of pazopanib is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8.
Maltese: Riżultati minn studji in vitro urew li l-metaboliżmu ta' pazopanib huwa mgħejjun primarjament minn CYP3A4, b'kontribuzzjoni anqas minn CYP1A2 and CYP2C8.
English: Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor ketoconazole (400 mg once daily) for 5 consecutive days resulted in a 66% and 45% increase in mean pazopanib AUC(0-24) and Cmax, respectively, relative to administration of pazopanib alone (400 mg once daily for 7 days).
Maltese: L-għoti ta' pazopanib (400 mg darba kuljum) flimkien mal-inibitur qawwi ta' CYP3A4 u P-gp ketoconazole (400 mg darba kuljum) għal 5 ijiem konsekuttivi wasslet għal żjieda ta' 66 % u 45 % flAUC(0-24) u Cmax medji ta' pazopanib, rispettivament, meta mqabbel mal-għoti ta' pazopanib waħdu (400 mg darba kuljum għal 7 tijiem).
English: Blood pressure should be monitored and managed promptly using a combination of anti-hypertensive therapy and dose modification of pazopanib (interruption and re-initiation at a reduced dose based on clinical judgement) (see sections 4.2 and 4.8).
Maltese: Il-pressjoni għandha tiġi ssorveljata u immaniġġata minnufih permezz ta' taħlita ta' terapija kontra l-pressjoni għolja u modifika fid-doża ta' pazopanib (interruzzjoni u bidu mill-ġdid b'doża mnaqqsa ibbażat fuq ġudizzju kliniku) (ara sezzjonijiet 4.2 u 4.8).
English: Clinical pharmacology studies, using pazopanib 800 mg once daily, have demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics of caffeine (CYP1A2 probe substrate), warfarin (CYP2C9 probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients.
Maltese: Studji kliniċi farmakoloġiċi, b'800 mg pazopanib darba kuljum, urew li l-pazopanib m'għandux effett kliniku relevanti fuq il-farmakokinetiċi tal-kaffeina (sustanza sonda li fuqha taġixxi l-CYP1A2), tal-warfarin (sustanza sonda li fuqha taġixxi l-CYP2C9), jew tal-omeprazole (sustanza sonda li fuqha taġixxi l-CYP2C19) f'pazjenti tal-kanċer.
English: In juvenile toxicity studies, when pre-weaning rats were dosed from day 9 post partum through to day 14 post partum, pazopanib caused mortalities and abnormal organ growth/maturation in kidney, lung, liver and heart, at a dose approximately 0.1 times the clinical exposure based on AUC in adult humans.
Maltese: Fi studji dwar tossiċità fiż-żagħżagħ, fejn firien qabel infatmu ingħataw doża minn jum 9 wara t-twelid sa jum 14 wara t-twelid, pazopanib ikkawża fatalitajiet u tkabbir mhux normali talorgani/maturazzjoni fil-kilwa, pulmun, fwied u qalb, b'doża ta' madwar 0.1 darbiet l-esponiment kliniku ibbażat fuq l-AUC f'adulti umani.
English: In vitro studies suggest that pazopanib is a substrate for P-gp and BCRP.
Maltese: In vitro jissuġerrixxu li l-pazopanib huwa sustanza li fuqha jaġixxu l-P-gp u l-BCRP.
English: What Votrient looks like and contents of the pack Votrient 200 mg film-coated tablets are capsule-shaped, pink with “GS JT” marked on one side.
Maltese: Il-pilloli miksijin b'rita ta' Votrient 200 mg huma forma ta' kapsula, roża, b' “GS JT” imnaqqxa fuq naħa waħda.
English: Leiomyosarcoma*
Maltese: Lejomajosarkoma*
English: Dyspnoea
Maltese: Disfonija
English: They are supplied in bottles of 30 or 90 tablets.
Maltese: Jiġu fi fliexken ta' 30 jew 90 pillola.
English: Table 7 Median steady-state pazopanib pharmacokinetics measured in subjects with hepatic impairment.
Maltese: Tabella 7 Farmakokinetika medjana ta' pazopanib fi stat fiss imkejjla f'individwi b'indeboliment epatiku.
English: In VEG108844, patients (N = 1110) with locally advanced and/or metastatic RCC who had not received prior systemic therapy, were randomised to receive either pazopanib 800 mg once daily continuously or sunitinib 50 mg once daily in 6-week cycles of dosing with 4 weeks on treatment followed by 2 weeks without treatment.
Maltese: F'VEG108844, pazjenti (N = 1110) b'RCC avvanzata lokalment u/jew metastatika li ma kinux irċevew terapija sistemika qabel, kienu randomized biex jirċievu pazopanib 800 mg darba kuljum kontinwament jew sunitinib 50 mg darba kuljum f'ċikli ta' dożaġg ta' 6 ġimgħat b'4 ġimgħat fuq kura segwit b'ġimagħtejn mingħajr kura.
English: Concomitant administration of pazopanib with uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) substrates (e.g. irinotecan) should be undertaken with caution since pazopanib is an inhibitor of UGT1A1 (see section 4.5).
Maltese: L-għoti ta' pazopanib flimkien ma' sustanżi li fuqhom jaġixxu uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) (eż. irinotecan) għandu jsir b'kawtela minħabba li l-pazopanib huwa inibitur ta' UGT1A1 (ara sezzjoni 4.5).
English: The safety and efficacy of pazopanib in RCC were evaluated in a randomised, double-blind, placebo-controlled multicentre study.
Maltese: Is-sigurtà u l-effikaċja ta' pazopanib f'RCC ġew evalwati fi studju randomiżżat, double-blind, f'ċentri multipli u b'kontrolli bi plaċebo.
English: Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)†
Maltese: Mikroanġjopatija trombotika (fosthom purpura tromboċitopenika trombotika u ssindrome uremiku emolitiku) †
English: Each film-coated tablet contains 400 mg pazopanib (as hydrochloride).
Maltese: Kull pillola miksija b'rita fiha 400 mg pazopanib (bħala hyrdrochloride).
English: Co-administration with potent P-gp or BCRP inhibitors may also alter the exposure and distribution of pazopanib, including distribution into the central nervous systems (CNS).
Maltese: L-għoti flimkien ma'inibituri potenti P-gp jew BCRP jistgħu wkoll ibiddel l-esponiment lejn, u d-distribuzzjoni ta'pazopanib, inkluż id-distribuzzjoni fis-sistema nervuża ċentrali (CNS).
English: Sixty-six per cent of placebo patients received post-study therapy compared to 30% of pazopanib patients.
Maltese: Sitta u sittin fil-mija tal-pazjenti fuq plaċebo rċevew terapija wara l-istudju mqabbla ma' 30% tal-pazjenti fuq pazopanib.
English: Blood and lymphatic system disorders f
Maltese: Disturbi tad-demm u tas-sistema limfatika f
English: Decreases in LVEF in subjects who had post-baseline and follow-up LVEF measurement were detected in 11% (15/140) in the pazopanib arm, compared with 3% (1/39) in the placebo arm.
Maltese: Kien osservat tnaqqis f'LVEF f'individwi li kellhom kejl wara l-linja bażi u LVEF ta' segwitu fi 11% (15/140) fil-grupp ta' pazopanib meta mqabbel ma' 3% (1/39) fil-grupp tal-plaċebo.
English: They are supplied in bottles of 30 or 60 tablets.
Maltese: Jiġu fi fliexken ta' 30 jew 60 pillola.
English: Other important serious adverse reactions identified in STS studies included venous thromboembolic events, left ventricular dysfunction and pneumothorax.
Maltese: Reazzjonijiet avversi serji importanti oħra identifikati fl-istudji dwar STS jinkludu avvenimenti tromboemboliċi venużi, disfunzjoni tal-ventriklu tax-xellug u pnewmotorax.
English: Administration of 1500 mg lapatinib (a substrate for and weak inhibitor of CYP3A4 and P-gp and a potent inhibitor of BCRP) with 800 mg pazopanib resulted in an approximately 50% to 60% increase in mean pazopanib AUC(0-24) and Cmax compared to administration of 800 mg pazopanib alone.
Maltese: L-għoti ta'1500 mg lapatinib (li jaġixxi fuq CYP3A4 u inibitur dgħajjef ta' CYP3A4 u P-gp u inibitur potenti ta' BCRP) ma' 800 mg pazopanib irriżulta f'żieda ta' madwar 50% sa 60% fil-konċentrażżjoni medja tal-AUC(0-24) u l-Cmax ta' pazopanib meta mqabbla ma' l-għoti ta' 800 mg pazopanib waħdu.
English: Pazopanib may have a greater impact on SN-38 disposition in subjects with the UGT1A1*28 polymorphism relative to subjects with the wild-type allele.
Maltese: Pazopanib jista' jkollu impatt akbar fuq id-dispożizzjoni ta' SN-38 f'individwi b'polimorfiżmu ta' UGT1A1*28 meta mqabbel malindividwi bl-allele li hija aktar komuni.
English: Votrient 400 mg film-coated tablets pazopanib
Maltese: Votrient 400 mg pilloli miksijin b'rita pazopanib
English: Hypothyroidism 83 (7%)
Maltese: Tromboċitopenija 86 (36% 7 (3%) 2 (<1%)
English: From the total of 435 patients in this study, 233 patients were treatment-naïve and 202 were second-line patients who had received one prior IL-2 or INF-based therapy.
Maltese: Mit-total ta' 435 pazjent f'dan l-istudju, 233 pazjent kienu inġenwi għat-trattament u 202 kienu t-tieni linja ta' pazjenti li kienu rċevew terapija fuq bażi
English: Patients (N = 435) with locally advanced and/or metastatic RCC were randomised to receive pazopanib 800 mg once daily or placebo.
Maltese: Pazjenti (N = 435) b'RCC lokali avvanzat u/jew metastatiku ġew randomizzati sabiex jirċievu jew 800 mg pazopanib darba kuljum jew plaċebo.
English: Pazopanib is not recommended in patients with severe hepatic impairment (defined as total bilirubin >3 x ULN regardless of the ALT value).
Maltese: Pazopanib mhux irrakkomandat f'pazjenti b'indeboliment epatiku sever (definit bħala bilirubin totali >3 x ULN indipendenti mill-valur ta' ALT).
English: In each treatment group, there was a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58% and 55%, respectively, for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42% and 45%, respectively, for placebo and pazopanib treatment arms).
Maltese: F'kull grupp ta' kura, kien hemm perċentwal kemmxejn ogħla ta' individwi fit-2+ linji ta' terapija sistemika minn qabel għall-marda avanzata (58% u 55%, rispettivament, għall-gruppi ta' kura bi plaċebo u b'pazopanib) meta mqabbel ma 0 jew 1 linji ta' terapija sistemika minn qabel (42% u 45% rispettivament għall-gruppi ta' kura bi plaċebo u pazopanib).
English: Pazopanib did not cause genetic damage when tested in genotoxicity assays (Ames assay, human peripheral lymphocyte chromosome aberration assay and rat in vivo micronucleus).
Maltese: Pazopanib ma kkawżax ħsara ġenetika meta ġie ttestjat f'assaġġi ġenotossiċi (assaġġ Ames, assaġġ talperipheral lymphocyte chromosome aberration tal-bniedem u l-mikronukleju in vivo tal-far).
English: In clinical studies with pazopanib, proteinuria has been reported.
Maltese: Fi studji kliniċi b'pazopanib, kienet irrappurtata il-proteinurja.
English: Rectal haemorrhage 2 (<1%) Enterocutaneous fistula 1 (<1%) Gastric haemorrhage 1 (<1%) Melaena
Maltese: Perforazzjoni tal-ilju 1 (<1%) Emorraġija fl-esofagu 1 (<1%) Emorraġija retroperitonali
English: a
Maltese: JIS
English: Haemorrhoidal haemorrhage
Maltese: Emorraġija millmurliti
English: Each film-coated tablet contains 200 mg pazopanib (as hydrochloride).
Maltese: Kull pillola miksija b'rita fiha 200 mg pazopanib (bħala hydrochloride).
English: Lethargy
Maltese: Rinorreja
English: Rare side effects (may affect up to 1 in 1,000 people): - inflammation of the lung (pneumonitis)
Maltese: Reazzjonijiet avversi rari (jistgħu jaffetwaw sa 1 minn 1,000 persuna): - infjammazzjoni tal-pulmun (pulmonite).
English: Human paediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including inhibition of growth (shortened limbs), fragile bones and remodelling of teeth, were present in juvenile rats at ≥10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adult humans) (see section 4.4).
Maltese: Pazjenti pedjatriċi umani għandhom riskju akbar ta' effetti fl-għadam u ssnien meta mqabbla mal-adulti, peress li dawn il-bidliet, inkluż inibizzjoni tat-tkabbir (riġlejn u dirgħajn mqassra), għadam fraġli u immudellar mill-ġdid tas-snien, kienu preżenti f'firien ta' età żgħira b'doża ta' ≥10 mg/kg/kuljum (ekwivalenti għal madwar 0.1-0.2 darbiet l-esponiment kliniku ibbażat fuq l-AUC f'adulti umani) (ara sezzjoni 4.4).
English: x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 290) Median 9.2 months; Placebo ------- (N = 145) Median 4.2 months; Hazard Ratio = 0.46, 95% CI (0.34, 0.62), P <0.0000001
Maltese: Medja 9.2 xhur; Plaċebo -------- (N = 145) Medjan 4.2 xhur; Proporzjon ta' Periklu = 0.46, 95% CI (0.34, 0.62), P <0.
English: Therefore, inhibitors and inducers of CYP3A4 may alter the metabolism of pazopanib.
Maltese: Għalhekk, inibituri u indutturi ta' CYP3A4 jistgħu jbiddlu l-metaboliżmu tal-pazopanib.
English: It cannot be excluded that pazopanib will affect the pharmacokinetics of substrates of OATP1B1 (e.g. statins, see “Effect of concomitant use of pazopanib and simvastatin” below).
Maltese: Ma jistax jiġi eskluż li l-pazopanib jaffettwa l-farmakokinetiċi ta' sustanżi li fuqhom jaġixxu l-OATP1B1 (eż. statins, ara “Effett tal-użu ta' pazopanib flimkien ma' simvastatin” taħt).
English: Votrient 400 mg film-coated tablets are capsule-shaped, white with “GS UHL” marked on one side.
Maltese: Il-pilloli miksijin b'rita ta' Votrient 400 mg huma forma ta' kapsula, bojod, b' “GS UHL” imnaqqxa fuq naħa waħda.
English: 2 years.
Maltese: 2 Kurva
English: Uncommon Oropharyngeal pain 3 (<1%) Bronchial haemorrhage 2 (<1%) Rhinorrhoea
Maltese: Mhux komuni Rinorreja Emorraġija fil-pulmun 2 (<1%) Pneumotoraċi
English: Votrient 200 mg film-coated tablets pazopanib
Maltese: Votrient 200 mg pilloli miksijin b'rita pazopanib
English: Pooled data from the pivotal RCC study (VEG105192, n=290), the extension study (VEG107769, n=71), the supportive Phase II study (VEG102616, n=225) and the randomised, open-label, parallel group Phase III non-inferiority study (VEG108844, n=557) were evaluated in the overall evaluation of safety and tolerability of pazopanib (total n=1149) in subjects with RCC (see section 5.1).
Maltese: III (VEG108844, n = 557) kienet mistħarrġa fl-evalwazjoni ġenerali tas-sigurtà u t-tolerabbiltà ta'pazopanib (total n = 1149) f'suġġetti b'RCC (ara sezzjoni 5.1).
English: The median duration of follow-up of subjects (defined as date of randomisation to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months].
Maltese: It-tul medjan ta' visti ta' wara talindividwi (definit bħala d-data ta' meta kienu randomised sad-data tal-aħħar kuntatt jew mewt) kien simili għaż-żewġ gruppi ta' kura (9.36 xahar għall-plaċebo [firxa 0.69 sa 23.0 xahar] u 10.
English: In vitro studies suggested that the oxidative metabolism of pazopanib in human liver microsomes is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8.
Maltese: Studji in vitro ssuġġerew li l-metaboliżmu ossidattiv ta' pazopanib fil-mikrożomi tal-fwied filbniedem iseħħ primarjament bl-għajnuna ta' CYP3A4, u b'kontribuzzjoni anqas minn CYP1A2 u CYP2C8.
English: 800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (defined either as normal bilirubin and any degree of alanine aminotransferase (ALT) elevation or as an elevation of bilirubin (>35% direct) up to 1.5 x upper limit of normal (ULN) regardless of the ALT value).
Maltese: F'pazjenti b'indeboliment epatiku ħafif jew moderat pazopanib għandu jingħata b'kawtela u b'monitoraġġ millqrib tat-tollerabilità. 800 mg pazopanib darba kuljum hija d-doża rrakkomandata f'pazjenti b'anormalitajiet ħfief fit-testijiet tas-serum tal-fwied (definiti jew bħala bilirubin normali u kwalunkwe grad ta' żieda fil-livell ta' alanine aminotransferase (ALT) jew inkella bħala żieda fil-livell ta' bilirubin (dirett >35%) sa 1.5 x l-ogħla limitu tan-normal (ULN) ikun xi jkun il-valur tal-ALT).
English: Elevated blood pressure levels (systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg) occurred early in the course of treatment (approximately 40% of cases occurred by day 9 and approximately 90% of cases occurred in the first 18 weeks).
Maltese: Livelli ta' pressjoni għolja (pressjoni sistolika≥150 mm Hg jew pressjoni dijastolika≥100 mm Hg) seħħet kmieni matul ittrattament (madwar 40% tal-każijiet seħħew mad-9 jum u madwar 90% seħħew fl-ewwel 18-il ġimgħa).
English: Uncommon Gastrointestinal haemorrhage
Maltese: Mhux komuni Emorraġija gastrointestinali
English: Mouth haemorrhage 2 (<1%) Upper gastrointestinal haemorrhage
Maltese: Emorraġija fil-ħalq 2 (<1%) Emorraġija fil-parti gastro-intestinali ta' fuq
English: You will be checked for any lung problems while you are taking Votrient.
Maltese: Każijiet ta' ipergliċemija kienu osservati waqt kura flimkien ma' ketoconazole.
English: Hepatic failure
Maltese: Indeboliment epatiku
English: Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets pazopanib
Maltese: IL-PRODOTT MEDIĊINALI Votrient 200 mg pilloli miksijin b'rita Votrient 400 mg pilloli miksijin b'rita
English: In a rat male fertility study, there was no effect on mating or fertility, but decreased testicular and epididymal weights were noted with reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentrations observed at exposures 0.3 times human exposure based on AUC.
Maltese: Fi studju ta' fertilità f'firien maskili, ma kien hemm l-ebda effett fuq it-tgħammir jew fertilità, imma ġie nnotat tnaqqis fil-piż testikulari u tal-epididimi b'tnaqqis fir-rata tal-produzzjoni tal-isperma, mobilità tal-isperma u l-konċentrazzjoni tal-isperma fit-testikoli u l-epididimu osservati f'esponimenti ta' 0.3 darbiet ta' esponimet uman ibbażat fuq AUC.
English: HR = hazard ratio; ITT = intent to treat; PFS = progression-free survival.
Maltese: PFS = sopravivenza mingħajr progressjoni;
English: Thrombocytopenia
Maltese: Tromboċitopenija Newtropenija
English: Very common Hypertension Common
Maltese: Ħakk ġeneralizzat
English: The median steady-state Cmax and AUC(0-24) values after administration of 200 mg pazopanib once daily in patients with severe hepatic impairment were approximately 18% and 15%, of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function.
Maltese: Il-valuri medjana ta' Cmax u AUC(0-24) fi stat fiss wara għoti ta' 200 mg pazopanib darba kuljum f'pazjenti b'indeboliment epatiku sever kienu madwar 18% u 15%, rispettivament, tal-valuri medjana korrispondenti wara għoti ta' 800 mg darba kuljum f'pazjenti b'funzjoni epatika normali.
English: The preclinical safety profile of pazopanib was assessed in mice, rats, rabbits and monkeys.
Maltese: Il-profil pri-kliniku ta' sigurtà ta' pazopanib kien assessjat fil-ġrieden, firien, fniek u xadini.
English: Reproductive system and breast disorder
Maltese: Disturbi fis-sistema riproduttiva u fissider
English: - increase in the number of red blood cells - sudden shortness of breath, especially when accompanied with sharp pain in the chest and /or rapid breathing (pulmonary embolism) - severe bleeding in the digestive system (such as stomach, oesophagus or intestine), or the kidneys, vagina and brain - heart rhythm disturbance (QT prolongation) - hole (perforation) in stomach or intestine - abnormal passages forming between parts of the intestine (fistula) - heavy or irregular menstrual periods - sudden sharp increase in blood pressure (hypertensive crisis) - inflammation of the pancreas (pancreatitis) - liver inflamed, not working well or damaged - yellowing of the skin or whites of the eyes (jaundice) - inflammation of the lining of the abdominal cavity (peritonitis) - runny nose - rashes which may be itchy or inflamed (flat or raised spots or blisters) - frequent bowel movements - increased sensitivity of the skin to sunlight - decreased feeling or sensitivity, especially in the skin
Maltese: vaġina u moħħ - disturbi fir-ritmu tal-qalb (titwil tal-intervall QT) - toqba (perforazzjoni) fl-istonku jew musrana - passaġġi abnormali li jiffurmaw bejn partijiet fil-musrana (fistula) - perjodi menstruwali qawwijin jew irregolari - żieda qawwija f'daqqa fil-pressjoni tad-demm (kriżi ipertensiva) - infjammazzjoni tal-frixa (pankreatite) - fwied iffjammat, jew mhux qed jaħdem sew, jew mħassar - ġilda safra jew l-abjad tal-għajnejn jisfar (suffejra) - infjammazzjoni tal-kisja tal-kavità abdominali (peritonite) - imnieħer iqattar - raxx li jista' jkun bil-ħakk jew iffjammat (tikek mal-ġilda jew mtellgħin jew nfafet) - ippurgar iżjed frekwenti - aktar sensitività tal-ġilda għad-dawl tax-xemx - tnaqqis fis-sensazzjoni jew sensittività, speċjalment fil-ġilda
English: - heart becomes less effective at pumping blood around the body (cardiac dysfunction) - slow heart beat - bleeding in the mouth, rectum or lung - dizziness - blurred vision - hot flushes - swelling caused by fluid of face, hands, ankles, feet or eyelids - tingling, weakness or numbness of the hands, arms, legs or feet - skin disorders, redness, itching, dry skin - nail disorders - burning, prickling, itching or tingling skin sensation - sensation of coldness, with shivering - excessive sweating - dehydration - muscle, joint, tendon or chest pain, muscle spasms - hoarseness - shortness of breath - cough - coughing up blood - hiccups - collapsed lung with air trapped in the space between the lung and chest, often causing shortness of breath (pneumothorax)
Maltese: jista' jmur għal ġol-pulmun tiegħek, u dan jista' jkun ta' periklu għal ħajja jew saħansitra fatali. - il-qalb issir inqas effettiva biex tippompja d-demm madwar il-ġisem (disfunzjoni kardijaka) - taħbit tal-qalb bil-mod - fsada fil-ħalq, rektum jew pulmun - sturdament - vista mċajpra - fwawar - nefħa fil-wiċċ, idejn, għekiesi, saqajn, jew tebqet il-għajn - tnemnin, dgħjufija fl-idejn, dirgħajn, riġlejn, jew saqajn jew jinħassu mtarraxin - disturbi fil-ġilda, ħmura, ħakk, ġilda niexfa - disturbi fid-dwiefer - sensazzjoni ta' ħruq, tingiż, ħakk jew tnemnim fil-ġilda - sensazzjoni ta' bard, flimkien ma' tregħid - għaraq eċċessiv - deidratazzjoni - uġigħ fil-muskoli, ġogi, tendons jew fis-sider, spażmu tal-muskoli - telf tal-vuċi - qtugħ ta' nifs - sogħla
English: Ninety-eight percent (98%) of subjects received prior doxorubicin, 70% prior ifosfamide, and 65% of subjects had received at least three or more chemotherapeutic agents prior to study enrolment.
Maltese: Tmienja u disgħin fil-mija (98%) tal-individwi kienu rċevew doxorubicin qabel, 70% ifosfamide qabel, u 65% tal-individwi kienu rċevew mill-inqas tliet sustanzi kimoterapewtiċi jew aktar qabel ma ddaħħlu fl-istudju.
English: The four principle pazopanib metabolites account for only 6% of the exposure in plasma.
Maltese: L-erba' metaboliti prinċipali ta' pazopanib huma responsabbli għal biss 6% tal-esponiment fil-plażma.
English: Results indicate that less than 4% of an orally administered pazopanib dose is excreted in the urine as pazopanib and metabolites.
Maltese: Riżultati jindikaw li inqas minn 4% ta' doża ta' pazopanib mogħtija mill-ħalq hija eliminata fl-awrina bħala pazopanib u metaboliti.
English: Anal haemorrhage Large intestine perforation
Maltese: Mhux komuni Kriżi ipertensiva Emorraġija